

*CircuLex*TM

**CML /N^e -(carboxymethyl) lysine
Mouse Monoclonal Antibody (Clone MK-5A10)
Cat# CY-M1028**

50 µg (1 mg/ml x 50 µL)

Clone Name	Applications	Species	Cross-reactivity	Molecular Wt.	Source Isotype
MK-5A10	ELISA		N/A	N/A	Mouse IgG1

Background Reducing sugars react with protein amino groups to form a diverse group of protein-bound moieties with fluorescent and cross-linking properties. These compounds, called advanced glycosylation end products (AGEs), have been implicated in the structural and functional alterations of proteins that occur during aging and long-term diabetes.

Although several AGE structures have been reported (1, 2), it was demonstrated that N^e-(carboxymethyl) lysine (CML) is a major antigenic AGE structure. CML concentration is also increased in patients who have diabetes with complications, including nephropathy (3–5), retinopathy (6), and atherosclerosis (7–9). CML is also recognized by receptor for AGE (RAGE), and CML-RAGE interaction activates cell signaling pathways such as NF- κ B and enhances the expression of vascular cell adhesion molecule-1 in human umbilical vein endothelial cells (10).

Specificity/Sensitivity: CML/N^e-(Carboxymethyl) lysine antibody detects the CML-adduct in various proteins.

Source/Purification: Monoclonal antibody is produced by immunizing mice with AGE-KLH. IgG is purified by protein A-sepharose chromatography.

Recommended Antibody Dilutions: Immunofluorescence assay for detection of CML adduct: 2-5 µg/mL. direct ELISA: 50-100 ng/mL.

Storage: Supplied in 10 mM HEPES KOH (pH 7.5), 150 mM NaCl, and 50 % glycerol. Store at -20°C.

Applications Key: **WB:** Western Blotting **IP:** Immunoprecipitation **IHC:** Immunohistochemistry **IC:** Immunocytochemistry **F:** Flow cytometry **E:** ELISA **FP:** Fluorescence Polarization assay

Species Cross-Reactivity Key: **H:** human **M:** mouse **R:** rat **Hm:** hamster **Mk:** monkey **Mi:** mink **C:** chicken **X:** *Xenopus* **Z:** zebra fish **All:** all species expected Species enclosed in parentheses are predicted to react based on 100% sequence homology. **N/A:** Not Applicable

Fig. 1 Direct ELISA for testing the reactivity of clone MK-5A10 against CML-adduct in CML modified BSA and BSA





Fig. 2 Competitive ELISA for measurement of CML-adduct in CML modified BSA using clone MK-5A10.



Direct ELISA Protocol

Solutions and Reagents

Note: Prepare solutions with Milli-Q or equivalently purified water.

Coating Buffer: 25 mM Sodium carbonate buffer (pH 9.0)

Wash Buffer TBS/T: 1X TBS, 0.1% Tween-20

Blocking Buffer: 1X TBS, 0.1% Tween-20 with 5% w/v nonfat dry milk; for 150 ml, add 15 ml 10X TBS to 135 ml water, mix. Add 7.5 g nonfat dry milk and mix well. While stirring, add 0.15 ml Tween-20 (100%).

10X TBS (Tris-buffered saline): To prepare 1 liter of 10X TBS: 24.2 g Tris base, 80 g NaCl; adjust pH to 7.0 with HCl (use at 1X).

Primary Antibody Dilution Buffer: 1X TBS, 0.1% Tween-20, 0.05 % NaN₃ with 2 % BSA; for 20 ml, add 2 ml 10X TBS to 18 ml water, mix. Add 0.4 g BSA and mix well. While stirring, add 20 µl Tween-20 (100%) and 100 µl of 10 % NaN₃.

Secondary Antibody Dilution Buffer: 1X TBS, with 2 % BSA; for 20 ml, add 2 ml 10X TBS to 18 ml water, mix. Add 0.4 g BSA and mix well.

Secondary Antibody: anti-mouse IgG antibody conjugated to horseradish peroxidase (HRP).

HRP Detection: 1 mM 3, 3', 5, 5'-tetramethylbenzidine 2HCl/TMB (KPL, Inc.) and 10 mM H₂O₂ in 20 mM Sodium citrate buffer (pH 5.5).

Stop Solution: 0.5 N H₂SO₄

ELISA Procedure

1. Make serial dilutions of CML-BSA (0.5 to 256 ng/ml) or sample.
2. Add 100 µl of diluted sample to each well in 96-well microtiter plate and incubate overnight at 4°C.
3. Wash 2 times with Wash Buffer.
4. Add 200 µl of Blocking Buffer to each well and incubate for 1.5 h at 37°C or overnight at 4°C.
5. Wash 4 times with Wash Buffer.
6. Add 100 µl of 0.1-0.4 µg/ml anti-Nε-(carboxymethyl) lysine /CML monoclonal antibody MK-5A10 and incubate for 1 hr at room temperature.
7. Wash wells five times with Wash Buffer making sure each well is filled completely. Remove residual Wash Buffer by gentle tapping or aspiration.
8. Add 100 µl of anti-mouse IgG antibody conjugated to horseradish peroxidase (HRP) and incubate for 1 hr at room temperature.
9. Wash wells five times with Wash Buffer making sure each well is filled completely. Remove residual Wash Buffer by gentle tapping or aspiration.
10. Add 100 µL of Substrate Reagent to each well and incubate at room temperature for 5-15 minutes.
11. Add 100 µL of Stop Solution to each well in the same order as the previously added Substrate Reagent.

12. Measure absorbance in each well using a spectrophotometric plate reader at dual wavelengths of 450/540 nm. Dual wavelengths of 450/550 or 450/595 nm can also be used. Read the plate at 450 nm if only a single wavelength can be used. Wells must be read within 30 minutes of adding the Stop Solution.

References:

- (1) Ikeda K, Higashi T, Sano H, Jinnouchi Y, Yoshida M, Araki T, Ueda S, Horiuchi S: *Biochemistry* **35**: 8075 –8083,1996
- (2) Reddy S, Bichler J, Wells-Knecht KJ, Thorpe SR, Baynes JW: *Biochemistry* **34**: 10872 –10878,1995
- (3) Makino H, Shikata K, Hironaka K, Kushiro M, Yamasaki Y, Sugimoto H, Ota Z, Araki N, Horiuchi S: *Kidney Int* **48**: 517 –526,1995
- (4) Suzuki D, Yagame M, Jinde K, Naka R, Yano N, Endoh M, Kaneshige H, Nomoto Y, Sakai H: *J Diabetes Complications* **10**: 314 –319,1996
- (5) Imai N, Nishi S, Suzuki Y, Karasawa R, Ueno M, Shimada H, Kawashima S, Nakamaru T, Miyakawa Y, Araki N, Horiuchi S, Gejyo F, Arakawa M: *Nephron* **76**: 153 –160,1997
- (6) Murata T, Nagai R, Ishibashi T, Inomuta H, Ikeda K, Horiuchi S: *Diabetologia* **40**: 764 –769,1997
- (7) Kume S, Takeya M, Mori T, Araki N, Suzuki H, Horiuchi S, Kodama T, Miyauchi Y, Takahashi K: *Am J Pathol.* **147**: 654 –667,1995
- (8) Sakata N, Imanaga Y, Meng J, Tachikawa Y, Takebayashi S, Nagai R, Horiuchi S, Itabe H, Takano T: *Atherosclerosis* **141**: 61 –75,1998
- (9) Sakata N, Imanaga Y, Meng J, Tachikawa Y, Takebayashi S, Nagai R, Horiuchi S: *Atherosclerosis* **142**: 67 –77,1999
- (10) Kislinger T, Fu C, Huber B, Qu W, Taguichi A, Du Yan S, Hofmann M, Yan SF, Pischetsrieder M, Stern D, Schmidt AM: *J Biol Chem* **274**: 31740 –31749,1999

Related Products

Cat.# CY-R2052: CML/Ne-(Carboxymethyl) lysine-BSA
Cat.# CY-R2053: CML/Ne-(Carboxymethyl) lysine-OVA

PRODUCED BY

CycLex Co., Ltd.
1063-103 Ohara, Tera-Sawaoka
Ina, Nagano 396-0002
Japan

Fax: 81-265-76-7618
e-mail: info@cyclex.co.jp
URL: <http://www.cyclex.co.jp>